Sherbrooke Park Advisers LLC Bristol Myers Squibb CO Transaction History

Sherbrooke Park Advisers LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$40.25 - $52.99 $236,146 - $310,892	5,867 Added 75.11%	13,678 $568 Million
Q1 2024 May 15, 2024	SELL	$47.98 - $54.4 $244,362 - $277,059	-5,093 Reduced 39.47%	7,811 $424 Million
Q4 2023 Feb 14, 2024	SELL	$48.48 - $57.85 $1.26 Million - $1.51 Million	-26,034 Reduced 66.86%	12,904 $662 Million
Q3 2023 Nov 14, 2023	BUY	$57.89 - $64.73 $1.25 Million - $1.4 Million	21,638 Added 125.08%	38,938 $2.26 Billion
Q2 2023 Aug 14, 2023	BUY	$63.71 - $70.74 $790,004 - $877,175	12,400 Added 253.06%	17,300 $1.11 Billion
Q1 2023 May 15, 2023	SELL	$65.71 - $74.53 $722,809 - $819,830	-11,000 Reduced 69.18%	4,900 $340 Million
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $1.09 Million - $1.29 Million	15,900 New	15,900 $1.14 Billion

2,533

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $124B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Sherbrooke Park Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Sherbrooke Park Advisers LLC with notifications on news.